10:20 AM EDT, 04/29/2024 (MT Newswires) -- Abbott Laboratories ( ABT ) said Monday that the US Food and Drug Administration has approved its Esprit BTK Everolimus Eluting Resorbable Scaffold System for people with chronic limb-threatening ischemia below the knee.

The Esprit BTK System, a dissolving stent, is designed to keep arteries open and deliver a drug, Everolimus, to support vessel healing prior to completely dissolving, the company said.

The LIFE-BTK trial, which assessed Abbott's Esprit BTK System, showed that it reduces disease progression and helps improves medical outcomes when compared with the current standard of care, balloon angioplasty, the firm said.

Price: 107.90, Change: +0.37, Percent Change: +0.34